For more than 50 years, DIA (the Drug Information Association), a non-profit association, has served as a global forum for all those involved in healthcare product development and lifecycle management to exchange knowledge and collaborate in a neutral setting. DIA is an essential resource that provides opportunities to extend debate and discussion to advance scientific and medical innovation. DIA fosters innovation to improve health and well-being worldwide by: Providing invaluable forums to exchange vital information and discuss current issues related to healthcare products, technologies, and services; Delivering customized learning experiences; Building, maintaining, and facilitating trusted relationships with and among individuals and organizations that drive and share DIA values and mandates; and offering a multidisciplinary neutral environment, respected globally for integrity and relevancy. DIA is your essential partner in catalyzing knowledge creation and sharing to accelerate healthcare product development.


This video gives a two minute review of the global navigation, content organization, global search, and filtering options available on the DIA platform.

This video explains the benefits of access to the recorded sessions of over 60 global meetings per year as a member of DIA. 

DIA NOW Sample video - Patient engagement initiatives are shown to increase chances of regulatory approval and accelerate development timelines.

FDARA Section 504 eliminated the orphan exemption for pediatric studies for cancer drugs and instead empowers the FDA to require pediatric assessments of new therapies.

This webinar recording will give an overview of challenges and successes of implementation of eCTD in both a small biotech setting and in academia, as these areas of industry face additional challenges that most midsize and large companies may not have.

A video overview of the valuable content that can be accessed as a DIA NOW user.



800 Enterprise Road, Suite 200

Horsham, PA 19044-3595


Phone: 215.442.6100

Fax: 215.442.6199

Contact: Michelle Rovner